Despite rising HIV rates and structural barriers to accessing care, American Indians and Alaska Natives do not have worse clinical outcomes when they're in care.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
People newly diagnosed with HIV must be able to access treatment and support, which could be improved if guided by people who have been taken the test themselves, researchers found.
Kistin Nolan, M.P.H., and colleagues helped pilot a retention program designed to accommodate the emotional turmoil that makes it more difficult for young people with HIV to successfully navigate the health care system.
Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.
"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.
On Aug. 30, 2018, the U.S. FDA approved doravirine as a separate formulation for use with ART and in a fixed-dose combination with generic tenofovir DF and lamivudine (3TC).
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.